|Articles|August 27, 2015

Admedus Adopts the Medidata Clinical Cloud® in Vaccine Study

Author(s)Applied Clinical Trials Editorial Staff

Admedus adopts the Medidata Clinical Cloud® to bring greater speed and efficiency to it’s genital herpes therapeutic vaccine study.

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that Australian-based specialist healthcare company Admedus is using its Medidata Clinical Cloud^® platform in its clinical development of a therapeutic vaccine for genital herpes.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
September 18th 2025
Viridian Therapeutics Completes Enrollment in Phase III Trial for Novel Monoclonal Antibody in Thyroid Eye Disease
September 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025

Trending on Applied Clinical Trials Online

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership

Viridian Therapeutics Completes Enrollment in Phase III Trial for Novel Monoclonal Antibody in Thyroid Eye Disease

© 2025 MJH Life Sciences^®

All rights reserved.